NEW ORLEANS--(BUSINESS WIRE)--TransMolecular, Inc., a developer of innovative oncology drugs through targeted delivery technologies, today announced final results from its Phase 2 clinical study comparing the toxicity and overall survival of three versus six intracavitary injections of its anti-cancer compound 131I-TM601 in the treatment of recurrent malignant glioma. The findings showed that intracavitary injections of 131I-TM601 were well tolerated and improved overall survival in a dose dependent manner. These findings will be presented at the 2009 Joint Meeting of the Society of NeuroOncology (SNO) and American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Section on Tumors in New Orleans, October 22-24.
